Effect of acid secretion blockade on acute gastric mucosal lesions induced by Tityus serrulatus scorpion toxin in anaesthetized rats.
Scorpion venom (TX) promotes gastric acid and pepsin secretion leading to acute gastric mucosal lesions (AGML), when injected in animals. The goal of the present study was to observe the effects of acid gastric secretion blockers over the incidence of TX-induced AGML in vivo. To verify this model, we used male albino rats, fasted 18-20 h (n=122) and anaesthetized with urethane (1.4 g/kg, i.p.). Their trachea and left femoral vein were both cannulated; the first to avoid airway obstructions during scorpion intoxication and the second for administration of saline, TX and acid blockers. Following the surgical procedure, the animals were divided in 10 groups of at least 10 animals each. Control groups were injected with NaCl 0.9% 1 ml/kg (n=10) or TX 375 microg/kg (n=32). Test groups (n=10, each) received atropine 5 mg/kg, cimetidine 10mg/kg, ranitidine 2.5mg/kg, ranitidine 5mg/kg, omeprazol 1 mg/kg, omeprazol 4 mg/kg, octreotide 80 and octreotide 100 microg/kg 10 min before the TX was injected. After 1h of intoxication, the stomach was resected for macroscopic study and the gastric secretion was collected for volume, pH and acid output assessment. We observed that all blockers were able to completely or partially prevent the TX-induced acid secretion as well as the AGML (p<0.05). Our data suggest the TX-induced AGML can be prevented by different class of acid blockers injected before the intoxication.
Melo
Júnio Rios
JR
Department of Surgery, School of Medicine, Universidade Federal de Minas Gerais (UFMG), Avenida Alfredo Balena, 190/4003, Bairro Santa Efigênia, CEP 30130-100, Belo Horizonte, MG, Brazil.
de Araújo
Gnana Keith Marques
GK
da Luz
Magda Maria Profeta
MM
da Conceição
Sérgio Alexandre
SA
Lisboa
Felipe Assis
FA
Moraes-Santos
Tasso
T
Cunha-Melo
José Renan
JR
D000208:Acute Disease; D000758:Anesthesia; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002927:Cimetidine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004336:Drug Antagonism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005744:Gastric Acid / Q000378:metabolism*; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D005765:Gastrointestinal Agents / Q000494:pharmacology*; D008297:Male; D009498:Neurotoxins / Q000032:analysis / Q000633:toxicity*; D015282:Octreotide / Q000494:pharmacology; D009853:Omeprazole / Q000494:pharmacology; D010434:Pepsin A / Q000378:metabolism; D011899:Ranitidine / Q000494:pharmacology; D051381:Rats; D012604:Scorpion Venoms / Q000032:analysis / Q000633:toxicity*; D013272:Stomach Diseases / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*
D004791:Enzyme Inhibitors; D005765:Gastrointestinal Agents; D009498:Neurotoxins; D012604:Scorpion Venoms; C003609:tityustoxin; D001285:Atropine; D002927:Cimetidine; D011899:Ranitidine; D010434:Pepsin A; D009853:Omeprazole; D015282:Octreotide